All Pathways
Obstetrics & GynecologyEmergency

Amniotic Fluid Embolism Management (SMFM 2016)

Amniotic Fluid Embolism Management (SMFM 2016): Suspected AFE → Classic Presentation → IMMEDIATE RESPONSE → A - Airway & Breathing → D - DIC/Coagulopath...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Suspected AFE

    Sudden cardiorespiratory collapse during labor or shortly after delivery

    1. Action

      Classic Presentation

      Recognize the clinical syndrome

      • Sudden hypotension or cardiac arrest
      • Hypoxia/respiratory distress
      • Altered mental status/seizures
      • Coagulopathy (may be delayed 10-30 min)
      • Fetal bradycardia if undelivered
      • Occurs during labor, cesarean, or <30 min postpartum
      1. Warning

        IMMEDIATE RESPONSE

        Activate emergency response NOW

        • Call CODE/Rapid Response
        • Call for anesthesia, OB, ICU, neonatal team
        • If cardiac arrest: Begin high-quality CPR
        • Prepare for perimortem cesarean if undelivered
        • Assign roles: compressions, airway, access, recorder
        1. Action

          A - Airway & Breathing

          Secure airway and support oxygenation

          • 100% FiO2
          • Early intubation likely needed
          • Positive pressure ventilation
          • Target SpO2 >94%
          • Avoid hyperventilation
          1. Action

            D - DIC/Coagulopathy Management

            Anticipate and treat massive hemorrhage

            • Activate Massive Transfusion Protocol
            • 1:1:1 ratio (pRBC:FFP:Platelets)
            • Cryoprecipitate: target fibrinogen >150-200 mg/dL
            • TXA 1g IV (if within 3 hours)
            • Point-of-care testing if available (TEG/ROTEM)
            • Avoid hypothermia - use warmers
            1. Action

              Right Heart Failure Support

              Initial phase often involves acute RV failure

              • Avoid fluid overload (worsens RV)
              • Consider inhaled nitric oxide
              • Consider ECMO in refractory cases
              • Inotropes: dobutamine, milrinone
              • Cardiology/cardiac surgery consultation
              1. Action

                Consider ECMO

                For refractory cardiogenic shock

                • VA-ECMO for cardiogenic shock
                • May bridge to recovery
                • Requires specialized center
                • Consider early transfer if available
                • Survival reported with ECMO support
                1. Outcome

                  ICU Admission

                  Continued intensive monitoring and support

                  • Invasive hemodynamic monitoring
                  • Serial labs: coags, lactate, organ function
                  • Neurologic assessment post-arrest
                  • Multidisciplinary team management
                  • Family support and communication
                  1. Outcome

                    Outcome & Documentation

                    Debrief and follow-up care

                    • Mortality 20-60% despite optimal care
                    • Survivors may have neurologic sequelae
                    • Document timeline and interventions
                    • Debrief with team
                    • Support for family regardless of outcome
            2. Action

              Hemorrhage Control

              Manage uterine atony and surgical bleeding

              • Uterotonics (oxytocin, methylergonovine, carboprost)
              • Uterine massage
              • Uterine tamponade balloon
              • Consider B-Lynch suture
              • Hysterectomy if refractory bleeding
              • Damage control surgery if coagulopathic
            3. Decision

              Diagnosis is Clinical

              No confirmatory test exists

              • Exclude other causes: PE, MI, anaphylaxis, sepsis
              • Hemorrhage/DIC supports diagnosis
              • Fetal squamous cells in blood NOT diagnostic
              • Consider differential: massive PE, aortic dissection
        2. Action

          C - Circulation

          Hemodynamic support

          • 2 large-bore IVs (14-16G)
          • Epinephrine 1mg IV q3-5min if arrest
          • Vasopressors: norepinephrine preferred
          • AVOID excessive fluid (risk pulmonary edema)
          • Target MAP >65 mmHg
          • Consider arterial line, central access
        3. Warning

          Perimortem Cesarean Section

          If undelivered and cardiac arrest - deliver within 5 minutes

          • Start within 4 minutes of arrest
          • Delivery by 5 minutes improves maternal/fetal outcomes
          • Do NOT delay for sterile prep
          • Delivery relieves aortocaval compression
          • May improve maternal resuscitation success
          • Continue CPR during and after cesarean

Guideline Source

SMFM Clinical Guideline #9: Amniotic Fluid Embolism

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • AFE is a clinical diagnosis - no confirmatory test
  • Extremely rare (1:40,000) - unpredictable and unpreventable
  • Mortality 20-60% even with optimal care
  • Pathophysiology not fully understood

Applicable Regions

USEUGlobal

US: Based on SMFM 2016 guideline with 2021 checklist update

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Amniotic Fluid Embolism Management (SMFM 2016)?

The Amniotic Fluid Embolism Management (SMFM 2016) is a emergency clinical algorithm for Obstetrics & Gynecology. It provides a structured decision tree to guide clinical decision-making, based on SMFM Clinical Guideline #9: Amniotic Fluid Embolism.

What guideline is the Amniotic Fluid Embolism Management (SMFM 2016) based on?

This algorithm is based on SMFM Clinical Guideline #9: Amniotic Fluid Embolism (DOI: 10.1016/j.ajog.2016.03.012).

What are the limitations of the Amniotic Fluid Embolism Management (SMFM 2016)?

Known limitations include: AFE is a clinical diagnosis - no confirmatory test; Extremely rare (1:40,000) - unpredictable and unpreventable; Mortality 20-60% even with optimal care; Pathophysiology not fully understood. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Amniotic Fluid Embolism Management (SMFM 2016) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free